OKYO Pharma (OKYO) deepens NCP program with new advisory board expert

Rhea-AI Filing Summary

OKYO Pharma filed a report highlighting the expansion of its Scientific Advisory Board with the appointment of ophthalmology expert Marta Sacchetti, MD, PhD. She brings extensive experience in corneal and ocular surface diseases and prior leadership as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici.

The filing reiterates the company’s focus on neuropathic corneal pain (NCP) and inflammatory eye diseases, centered on its investigational drug Urcosimod. Urcosimod is the first therapy to receive an IND specifically for NCP and has Fast Track designation from the U.S. FDA. OKYO notes positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2 NCP trial involving 18 patients, and prior statistical significance in multiple endpoints in a 240‑patient Phase 2 dry eye disease study. The company recently completed a Phase 2 NCP trial and plans a 150‑patient Phase 2b/3 multiple-dose study of Urcosimod for NCP in the first half of the year.

Key Figures

Fast Track status: Fast Track designation NCP Phase 2 trial size: 18 patients Dry eye Phase 2 trial size: 240 patients +2 more

5 metrics

Fast Track status Fast Track designation Granted by U.S. FDA for Urcosimod in neuropathic corneal pain

NCP Phase 2 trial size 18 patients Randomized, placebo-controlled, double-masked Phase 2 NCP trial

Dry eye Phase 2 trial size 240 patients Phase 2 multi-center trial in dry eye disease

Planned Phase 2b/3 trial size 150 patients Planned multiple-dose Urcosimod study in NCP

Program stage Phase 2 completed Urcosimod in neuropathic corneal pain

Key Terms

Scientific Advisory Board, neuropathic corneal pain, Fast Track designation, Investigational New Drug, +2 more

6 terms

Scientific Advisory Board financial

"announced the expansion of their Scientific Advisory Board (SAB) with the appointment"

A scientific advisory board is a group of independent experts—often scientists, clinicians or technical specialists—who give a company guidance on its research, product development and regulatory strategy. For investors, their role is like an external quality check: credible experts can reduce technical risk, improve the chance of regulatory approval or successful products, and boost confidence that management’s science claims are realistic and well-directed.

neuropathic corneal pain medical

"developing investigational therapies for the treatment of neuropathic corneal pain (NCP)"

Neuropathic corneal pain is chronic, often severe eye pain caused by damage or malfunction in the tiny nerves of the cornea, where the eye surface can feel burning, stinging, or like something is in it despite little visible damage. It matters to investors because it represents a persistent, hard-to-treat medical need that drives demand for new drugs, diagnostics, devices and regulatory approvals, similar to how fixing a frayed electrical wire stops false alarm signals.

Fast Track designation regulatory

"has been granted Fast Track designation by the U.S. Food and Drug Administration"

A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.

Investigational New Drug regulatory

"first investigational therapy to receive an IND specifically for the treatment of neuropathic corneal pain"

An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.

Phase 2 trial medical

"randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients"

A phase 2 trial is an intermediate-stage clinical study that tests whether a new treatment works and is reasonably safe in a group of patients who have the condition it targets. Think of it as a field test of a prototype product: it checks real-world effectiveness and side effects on a modest number of users to decide whether the treatment should move to larger, definitive testing. Investors watch phase 2 results because positive outcomes can sharply increase the likelihood of regulatory approval and future sales, while failures often halt development.

dry eye disease medical

"placebo-controlled trial to treat dry eye disease"

Dry eye disease is a chronic condition where the eyes do not make enough tears or the tears evaporate too quickly, causing irritation, blurred vision and sensitivity to light — imagine having tiny grains of sand or a windshield with streaks that never clear. It matters to investors because it creates steady demand for prescription drugs, medical devices and diagnostic tests; treatments can be long‑term, subject to regulatory approval and insurance coverage, and successful products can capture large, recurring revenue streams.

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

May 2026

Commission File Number: 001-41386

OKYO Pharma LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 19, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing the expansion of their Scientific Advisory Board (SAB) with the appointment of Marta Sacchetti, MD, PhD. This appointment further enhances the Company’s global scientific network with premier European specialists.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	OKYO Pharma LTD
Date: May 19, 2026	By:	/s/ Keeren Shah
	Name:	Keeren Shah
	Title:	Chief Financial Officer

3

EXHIBIT INDEX

Exhibit No.		Description
99.1		News Announcement, dated May 19, 2026

4

Exhibit 99.1

 

OKYO Expands Scientific Advisory Board with the Appointment of International Expert Marta Sacchetti, MD, PhD

	●	Dr. Sacchetti brings international expertise in clinical and translational research on ocular inflammatory and degenerative disease
	●	OKYO’s introduction to the broader ophthalmology community at ASCRS drove strong engagement at Eyecelerator and ARVO

London and New York, NY, May 19, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced the expansion of their Scientific Advisory Board (SAB) with the appointment of Marta Sacchetti, MD, PhD. This appointment further enhances the Company’s global scientific network with premier European specialists.

“Our world class Scientific Advisory Board is further strengthened by the addition of Marta Sacchetti, MD, PhD,” said Flavio Mantelli, MD, PhD, Chief Medical Officer of OKYO Pharma. “Her expertise in neuro-inflammatory corneal diseases brings critical insight into addressing the underlying nerve dysfunction driving neuropathic corneal pain (NCP) and will help shape our global clinical development strategy and execution.”

Marta Sacchetti, MD, PhD is Associate Professor of Ophthalmology at Link University in Rome, Italy and brings extensive clinical, research, and industry experience in cornea and ocular surface diseases. Dr. Sacchetti’s previous experience as Global Head of Clinical Development, Ophthalmology & Neurotrophins at Dompé Farmaceutici will further strengthen the MAB’s global expertise in targeted nerve regeneration, modulating pain signaling, and advanced diagnostic insight. Her research focuses on degenerative, allergic, and neuroimmune diseases of the cornea and ocular surface. She authored numerous publications in international peer reviewed journals, abstracts for national and international conferences, and ophthalmology book chapters.

Urcosimod is the first investigational therapy to receive an IND specifically for the treatment of neuropathic corneal pain and has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).

About Neuropathic Corneal Pain (NCP)

Neuropathic corneal pain (NCP) is a chronic, often debilitating condition characterized by severe pain and sensitivity of the eyes, and in some cases the face or head. It is thought to result from damage or dysfunction of corneal sensory nerves, often in combination with inflammatory processes, and may occur in patients with a range of underlying ophthalmic conditions. There are currently no FDA-approved therapies specifically for NCP, resulting in patients being treated with limited or no success using various topical and systemic medications in an off-label manner.

About Urcosimod (formerly called OK-101)

Urcosimod is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye responsible for the inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has been shown to produce anti-inflammatory and pain-reducing activities in a mouse model of dry eye disease and in a neuropathic corneal pain mouse model, respectively. OKYO recently announced positive data on NCP pain reduction in a randomized, placebo-controlled, double-masked Phase 2 trial involving 18 neuropathic corneal pain patients. Urcosimod showed clear statistical significance in multiple endpoints in an earlier 240-patient Phase 2, multi-center, double-masked, placebo-controlled trial to treat dry eye disease.

About OKYO Pharma

OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and inflammatory eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO is focused on the discovery and development of novel molecules to treat neuropathic corneal pain and other ocular diseases. OKYO recently completed a successful phase 2 trial of its flagship drug urcosimod in patients with NCP and plans to initiate a 150-patient Phase 2b/3 multiple-dose study of urcosimod to treat NCP in the first half of this year.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd

Paul Spencer

Business Development, and Investor Relations

+44 (0) 207 495 2379

Email: info@okyopharma.com

FAQ

What does OKYO Pharma (OKYO) announce in this Form 6-K?

OKYO Pharma announces the expansion of its Scientific Advisory Board with the appointment of Marta Sacchetti, MD, PhD. The company also reiterates development progress for Urcosimod, its investigational therapy for neuropathic corneal pain and inflammatory eye diseases, including recent Phase 2 trial results.

Who is Marta Sacchetti and what will she contribute to OKYO Pharma (OKYO)?

Marta Sacchetti, MD, PhD is an Associate Professor of Ophthalmology at Link University in Rome. She brings extensive clinical, research, and industry experience in cornea and ocular surface diseases and is expected to help shape OKYO’s global clinical development strategy for neuropathic corneal pain.

What is Urcosimod and what eye conditions is OKYO Pharma (OKYO) targeting?

Urcosimod is a lipid-conjugated chemerin peptide agonist of the ChemR23 receptor, developed for neuropathic corneal pain and inflammatory eye diseases. It targets immune cells and neurons involved in inflammation and pain signaling, aiming to treat chronic eye pain where no FDA-approved NCP therapies currently exist.

What clinical trial results for Urcosimod does OKYO Pharma (OKYO) highlight?

OKYO highlights positive pain-reduction data from a randomized, placebo-controlled, double-masked Phase 2 trial in 18 neuropathic corneal pain patients. It also reports clear statistical significance in multiple endpoints from an earlier 240-patient Phase 2 trial in dry eye disease, supporting Urcosimod’s anti-inflammatory and analgesic profile.

What regulatory status does Urcosimod have according to OKYO Pharma (OKYO)?

Urcosimod is described as the first investigational therapy to receive an IND specifically for neuropathic corneal pain and has been granted Fast Track designation by the U.S. Food and Drug Administration. These designations highlight regulatory recognition of the high unmet need in NCP treatment.

What are OKYO Pharma’s (OKYO) upcoming clinical plans for Urcosimod?

OKYO states it recently completed a Phase 2 trial of Urcosimod in neuropathic corneal pain and plans to initiate a 150-patient Phase 2b/3 multiple-dose study for NCP in the first half of the year. This next trial is intended to further evaluate efficacy and safety.

Why is neuropathic corneal pain (NCP) an important focus for OKYO Pharma (OKYO)?

Neuropathic corneal pain is a chronic, often debilitating condition caused by corneal nerve damage or dysfunction, frequently with inflammation. There are no FDA-approved therapies specifically for NCP, so patients are treated off-label with limited success, representing a significant unmet medical need OKYO aims to address.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 14.3 KB
• EX-99 GRAPHIC 7.5 KB